What diseases can Dasatinib/Startaxil tablets treat?

Dasatinib is a second-generation oral tyrosine kinase inhibitor specifically designed to target the BCR-ABL fusion protein, which is a key molecular driver of chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias (ALL). The BCR-ABL fusion gene causes abnormal proliferation and inhibition of apoptosis of leukemia cells by continuously activating the tyrosine kinase signaling pathway. Dasatinib irreversibly binds to BCR-ABL kinase and inhibits its downstream signaling, thereby blocking the growth of leukemia cells and restoring normal blood cell production.

In clinical application, dasatinib is suitable for patients at all stages of CML, including chronic phase, accelerated phase, and patients who progress from chronic phase to blast crisis phase. Compared with the first-generation tyrosine kinase inhibitor imatinib (Imatinib), dasatinib provides a stronger inhibitory effect on partially drug-resistant or intolerant patients, and is especially active against drug-resistant mutations such as T315I. In addition, dasatinib is also approved for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), including adult and adolescent patients who cannot tolerate or have an inadequate response to standard chemotherapy.

Dasatinib’s oral dosage form and strong target selectivity give it significant advantages in long-term maintenance treatment and relapse prevention. Studies have shown that patients treated with dasatinib are generally better than traditional chemotherapy regimens in achieving complete molecular remission (CMR) and disease-free survival, with controllable side effects and high safety. In addition, dasatinib also shows good synergistic anti-leukemia effects in combination with chemotherapy or other targeted drugs, providing more treatment options for high-risk patients.

In summary, dasatinib is not only a core targeted drug for chronic myelogenous leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia, but also an important component of modern precision hematology treatment.

Reference materials:https://go.drugbank.com/drugs/DB01254